<DOC>
	<DOCNO>NCT01712399</DOCNO>
	<brief_summary>A clinical study investigate safety mavrilimumab , antibody develop treatment moderate severe rheumatoid arthritis , inflammatory condition affect joint .</brief_summary>
	<brief_title>A Long Term Safety Study Mavrilimumab Adult Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>Despite therapeutic improvement recent biologic agent approve rheumatoid arthritis ( RA ) , still significant unmet medical need treatment subject chronic disease achieve faster , complete response , high rate remission . This study open-label extension study subject participate one qualifying development program study mavrilimumab . Participation study allow subject continue receive long-term treatment mavrilimumab . The data study provide evaluation long-term safety mavrilimumab adult subject RA . In addition , long-term exploratory efficacy outcomes joint damage disability evaluate .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects complete treatment period qualify study fail respond adequately investigational product predefined time point qualify study regardless initial randomization . No evidence clinically uncontrolled respiratory disease confirm local pulmonologist Subjects permanently discontinue investigational product previous qualify study . Any new condition worsen preexist condition define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>